{"filing":{"accession_number":"0001171843-26-006161","cik":"0001069530","ticker":"FLNA","company_name":"FILANA THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-09-22","report_date":"2026-09-22","primary_document":"f8k_092226.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1069530/000117184326006161/f8k_092226.htm"},"events":[{"id":34191,"run_id":31459,"accession_number":"0001171843-26-006161","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"The FDA has lifted a clinical hold on Filana's IND application for simufilam in TSC-related epilepsy, enabling the company to proceed with a Phase 2a proof-of-concept study with patient screening expected to begin in Q1 2027. This removal of a significant development barrier is a material regulatory milestone that directly advances the company's lead drug program.","company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","filing_date":"2026-09-22","form":"8-K","submitted_at":null,"items":[{"id":37859,"accession_number":"0001171843-26-006161","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses that the FDA has lifted a clinical hold on Filana's investigational drug simufilam, enabling the company to proceed with a Phase 2a proof-of-concept study in TSC-related epilepsy with patient screening expected to begin in Q1 2027. This is a material regulatory milestone and operational development event—the removal of a clinical hold is a significant positive development for a biotech company's drug development program, directly enabling advancement of a key clinical trial. While not fitting the specific categories of earnings, M\u0026A, litigation, or other named event types, this is clearly a material operational/regulatory milestone that would affect a reasonable investor's assessment of the company's development progress and prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T12:02:28.671508+00:00","company_name":"","ticker":null,"filing_date":""},{"id":37860,"accession_number":"0001171843-26-006161","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The FDA has lifted a clinical hold on Filana's IND application for simufilam in TSC-related epilepsy, enabling the company to proceed with a Phase 2a proof-of-concept study. This is a material regulatory milestone that removes a significant development barrier and allows the company to advance its lead program toward patient enrollment expected in Q1 2027. While this is a positive operational/regulatory event rather than a negative event like a covenant breach or going concern, it materially affects the company's ability to execute its development strategy and would influence a reasonable investor's assessment of near-term progress and value.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T12:02:28.671508+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37859,"accession_number":"0001171843-26-006161","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses that the FDA has lifted a clinical hold on Filana's investigational drug simufilam, enabling the company to proceed with a Phase 2a proof-of-concept study in TSC-related epilepsy with patient screening expected to begin in Q1 2027. This is a material regulatory milestone and operational development event—the removal of a clinical hold is a significant positive development for a biotech company's drug development program, directly enabling advancement of a key clinical trial. While not fitting the specific categories of earnings, M\u0026A, litigation, or other named event types, this is clearly a material operational/regulatory milestone that would affect a reasonable investor's assessment of the company's development progress and prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T12:02:28.671508+00:00","company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","filing_date":"2026-09-22"},{"id":37860,"accession_number":"0001171843-26-006161","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The FDA has lifted a clinical hold on Filana's IND application for simufilam in TSC-related epilepsy, enabling the company to proceed with a Phase 2a proof-of-concept study. This is a material regulatory milestone that removes a significant development barrier and allows the company to advance its lead program toward patient enrollment expected in Q1 2027. While this is a positive operational/regulatory event rather than a negative event like a covenant breach or going concern, it materially affects the company's ability to execute its development strategy and would influence a reasonable investor's assessment of near-term progress and value.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T12:02:28.671508+00:00","company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","filing_date":"2026-09-22"}]}